EyeGate Pharma Announces At The Market Issuance Program
May 24 2016 - 5:00PM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”)
announced today that it has entered into an At The Market Issuance
("ATM") Sales Agreement, dated May 24, 2016, with H.C. Wainwright
& Co., LLC (the “Sales Agent”), under which the Company may, at
its discretion and from time to time during the term of the ATM
Sales Agreement, sell up to a maximum of 1,319,289 shares of its
common stock through ATM issuances on the NASDAQ Capital
Market. The Sales Agent will act as sales agent for any sales
made under this new ATM program. The shares of common stock
will be sold at market prices prevailing at the time of the sale of
such shares and, as a result, sale prices may vary.
In connection with the execution of the ATM Sales
Agreement with the Sales Agent, the Company has filed with the
United States Securities and Exchange Commission (the “SEC”) a
prospectus supplement to its shelf registration statement on Form
S-3 (333-210557) filed with the SEC on April 1, 2016, which was
declared effective by the SEC on May 6, 2016.
The shelf registration statement on Form S-3 and
the prospectus supplement for this offering are available on the
SEC’s website (www.sec.gov). Alternatively, the Sales Agent
will provide copies of these documents upon request by contacting
H.C. Wainwright & Co., LLC, 430 Park Avenue, 4th Floor, New
York, NY 10022 or placements@hcwco.com.
This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy
any of the common shares, nor shall there be any sale of the common
shares in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About EyeGate:
EyeGate is a clinical-stage specialty
pharmaceutical company that is focused on developing and
commercializing therapeutics and drug delivery systems for treating
diseases of the eye. EGP-437, the Company’s first and only product
in clinical trials, incorporates a reformulated topically active
corticosteroid, Dexamethasone Phosphate that is delivered into the
ocular tissues through EyeGate’s proprietary innovative drug
delivery system, the EyeGate® II Delivery System. In addition,
EyeGate is developing, through its wholly-owned Jade subsidiary,
products using cross-linked thiolated carboxymethyl hyaluronic acid
(“CMHA-S”), a modified form of the natural polymer hyaluronic acid
(HA), which possesses unique physical and chemical properties such
as viscoelasticity and water retention. The ability of CMHA-S to
adhere longer to the ocular surface, resist degradation and protect
the ocular surface makes it well-suited for treating various ocular
surface injuries. EyeGate intends to initiate a clinical study for
Jade’s lead product candidate for corneal epithelial defects. For
more information, please visit www.EyeGatePharma.com.
Safe Harbor Statement:
Some of the statements in this press release are
“forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product, and
those of Jade Therapeutics, Inc., a wholly owned subsidiary of
EyeGate, as well as the success thereof, with such approvals or
success may not be obtained or achieved on a timely basis or at
all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, certain risk
factors described under the heading “Risk Factors” contained in
EyeGate’s Annual Report on Form 10-K filed with the SEC on March
30, 2016, EyeGate’s Quarterly Report on Form 10-Q filed with the
SEC on May 13, 2016 or described in EyeGate’s other public filings.
EyeGate’s results may also be affected by factors of which EyeGate
is not currently aware. The forward-looking statements in this
press release speak only as of the date of this press release.
EyeGate expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Contact:
Lee Roth / Joseph Green
The Ruth Group for EyeGate Pharmaceuticals
646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
Eyegate Pharmaceuticals (NASDAQ:EYEGW)
Historical Stock Chart
From Nov 2024 to Dec 2024
Eyegate Pharmaceuticals (NASDAQ:EYEGW)
Historical Stock Chart
From Dec 2023 to Dec 2024